Date: 2015-09-24
Type of information: R&D agreement
Compound:
Company: Regeneron Pharmaceuticals (USA - NY) Icahn School of Medicine
Therapeutic area:
Type agreement: R&D
Action mechanism: monoclonal antibody
Disease:
Details: * On September 24, 2015, Regeneron Pharmaceuticals and The Experimental Therapeutics Institute (ETI) at the Icahn School of Medicine at Mount Sinai announced that they have entered into an agreement with the goal of accelerating the discovery of fully human antibodies directed against therapeutic targets being researched by Mount Sinai investigators. Regeneron will provide the ETI with access to VelocImmune® technology and potential financial support to use the company's proprietary antibody discovery platform to generate antibodies against targets of interest and explore potential therapeutic applications for human disease. ETI will undertake preclinical research, and Regeneron has an exclusive option to negotiate a license to the antibody for future clinical development and commercialization.
Financial terms:
Latest news:
